Litigation
Celgene Corporation v. Cipla Ltd. et al.
settled/consent judgmentAuto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2019-07-03
- Terminated
- 2020-12-14
Patents at issue (3)
Plaintiffs (1)
Defendants (2)
Summary
Celgene sued Cipla and a Cipla USA affiliate in D.N.J. over generic lenalidomide. The asserted patents included '800, '217, '569, '498, '095, '621, '622, '740, '717, and '120; a stipulated consent judgment was entered December 14, 2020. The case number was not confirmed in the sources.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).